Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

Jorge E. Cortes, Michael J. Mauro, Alexis Visotcky, Srinivas K Tantravahi, James E Thompson, Jay Yang, Arielle Baim, Yan Gao, Sonia Maldonado-Schmidt, Claire Olig, Kathryn E. Flynn, Jerald P. Radich, Ehab L. Atallah

Blood (2024) 144 (Supplement 1): 6601.

https://doi.org/10.1182/blood-2024-207884

Published: 2024

Journal Articles

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Nicole R. Grieselhuber, Praneeth Baratam, Anjali S. Advani, Abdulraheem Yacoub, Don A. Stevens, Ahmed Aribi, Ben K. Tomlinson, Jay Yang, Pankit Vachhani, Joseph G Jurcic, Caspian H. Oliai, Jessica Liegel, Edward Pearson, Anna Van Rhenen, Marcello Rotta, Kapil Rathi, Juan Pinelli, Tara Chen, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 1840.

https://doi.org/10.1182/blood-2024-199634

Published: 2024

Journal Articles

Inclusion Matters: Effective AML Treatment with HMA/Venetoclax for Older Jehovah's Witnesses

Aditi Sharma, Danielle Blake, Jay Yang

Blood (2024) 144 (Supplement 1): 6077.

https://doi.org/10.1182/blood-2024-211287

Published: 2024

Journal Articles

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Jorge E. Cortes, Justin M. Watts, Eunice S. Wang, Jay Yang, Shira N. Dinner, Maria R. Baer, Gail J. Roboz, William B. Donnellan

Blood (2024) 144 (Supplement 1): 4600.

https://doi.org/10.1182/blood-2024-204039

Published: 2024

Journal Articles

Clinical and Molecular Characteristics of RAS and RAS-like Mutational Signature in Acute Myeloid Leukemia

Vikram Dhillon, Jeff Aguilar, Paul Kim, Dakshin Padmanabhan, Jay Yang, Gregory Dyson, David Carr, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian

Blood (2024) 144 (Supplement 1): 842.

https://doi.org/10.1182/blood-2024-212313

Published: 2024

Journal Articles

An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation

Dipenkumar Modi, Jay Yang, Seongho Kim, Asfar Azmi, Emily Tolksdorf, Christiane A. Houde, Jeffrey A. Zonder

Blood (2024) 144 (Supplement 1): 3123.4.

https://doi.org/10.1182/blood-2024-209059

Published: 2024

Journal Articles

Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia

Sandhya Dhiman, Md. Hafiz Uddin, Vikram Dhillon, Jeff Justin Aguilar, Amro Aboukameel, Husain Khan, Sahar Bannoura, Jay Yang, Gregory Dyson, Steven Buck, Asfar Azmi, Lisa Polin, Francis Burrows, Linda Kessler, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian

Blood (2024) 144 (Supplement 1): 2768.

https://doi.org/10.1182/blood-2024-206075

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Journal Articles

Clonal Evolution of TP53 Configurations with Treatment Predict Prognosis in Myeloid Neoplasms

Dakshin Padmanabhan, Jeff Aguilar, Paul Kim, Sandhya Dhiman, Asmita Shukla, Vikram Dhillon, Sushmitha Nanja Reddy, David Carr, Jay Yang, Julie Boerner, Jaroslaw Maciejewski, Suresh Kumar Balasubramanian

Blood (2024) 144 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2024-210037

Published: 2024

Journal Articles

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

Eunice S. Wang, Jorge E. Cortes, Justin M. Watts, Brian A. Jonas, Andrew H Wei, Jay Yang, Joseph G Jurcic, Gail J. Roboz, Karen Seiter, Alice Mims, Karen Yee, Brent Ferrell, Shira N. Dinner, William B. Donnellan, William Blum, Francois Di Trapani, Hua Tian, Stephane De Botton

Blood (2024) 144 (Supplement 1): 1514.

https://doi.org/10.1182/blood-2024-198504

Published: 2024

Journal Articles

U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

Ehab L. Atallah, Michael S. Broder, Onyee Chan, Hannah Dalglish, Kathryn E. Flynn, Jeffrey Gilreath, Marisa Hine, Anthony M. Hunter, Michael J. Mauro, Javier Pinilla-Ibarz, Lindsay A.M. Rein, Neil P. Shah, Evan Stemper, Srinivas K Tantravahi, Jay Yang

Blood (2024) 144 (Supplement 1): 5052.

https://doi.org/10.1182/blood-2024-194617

Published: 2024

Journal Articles

Longitudinal Sequencing to Investigate Clonal Evolution in Myeloid Neoplasms

Asmita Shukla, Dakshin Padmanabhan, Paul Kim, Jeff Aguilar, Sushmitha Nanja Reddy, Vikram Dhillon, David Carr, Jay Yang, Julie Boerner, Suresh Kumar Balasubramanian

Blood (2024) 144 (Supplement 1): 4254.

https://doi.org/10.1182/blood-2024-212206

Published: 2024

Journal Articles

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

Jorge E. Cortes, Gail J. Roboz, Justin M. Watts, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, Brent Ferrell, Jay Yang, Eunice S. Wang, William Blum, Alice Mims

Blood (2024) 144 (Supplement 1): 2886.

https://doi.org/10.1182/blood-2024-201710

Published: 2024

Journal Articles

A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS

Amir T. Fathi, Aleksandra Filipovic, Keri Maher, Dale G Schaar, Rabin Niroula, Joseph J. Maly, Deepa Jaykumar, Noah Merin, Jay Yang, Jorge R. Galvez Silva, Varun Gang, Taylor Meeks, Christopher Korth, Guenther Koehne

Blood (2024) 144 (Supplement 1): 1499.

https://doi.org/10.1182/blood-2024-209848

Published: 2024

Journal Articles

The Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit the Growth of MLL-r AML

Md. Hafiz Uddin, Amro Aboukameel, Sharif hasan Siddiqui, Husain Khan, Sahar Bannoura, Abhinav Deol, Jay Yang, Gregory Dyson, Asfar Azmi, Lisa Polin, Jaroslaw P. Maciejewski, Suresh Kumar Balasubramanian

Blood (2023) 142 (Supplement 1): 4168.

https://doi.org/10.1182/blood-2023-190638

Published: 2023

Journal Articles

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7434.

https://doi.org/10.1182/blood-2023-188683

Published: 2023

Journal Articles

Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)

Jorge Cortes, Jay Yang, Sangmin Lee, Shira N. Dinner, Eunice S. Wang, Maria R. Baer, William B. Donnellan, Justin M. Watts

Blood (2023) 142 (Supplement 1): 1872.

https://doi.org/10.1182/blood-2023-187404

Published: 2023

Journal Articles

Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia

Eunice S. Wang, Brian A. Jonas, Justin M. Watts, Joseph Jurcic, P. Brent Ferrell, Jr., Shira N. Dinner, Jay Yang, Karen Seiter, Alice Mims, William B. Donnellan, William Blum, Jorge Cortes

Blood (2023) 142 (Supplement 1): 6047.

https://doi.org/10.1182/blood-2023-187584

Published: 2023

Journal Articles

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

Jorge Cortes, Joseph Jurcic, Maria R. Baer, William Blum, P. Brent Ferrell, Jr., Brian A. Jonas, Sangmin Lee, Alice Mims, Shyam Ajay Patel, Gary J. Schiller, Jay Yang, Justin M. Watts

Blood (2023) 142 (Supplement 1): 2888.

https://doi.org/10.1182/blood-2023-187861

Published: 2023

Journal Articles

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Blood (2023) 142 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2023-179963

Published: 2023

NARROW

First Results of Asciminib As Initial Therapy with Addition of Lower Dose Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia Who Do Not Achieve a Deep Molecular Remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)

PF-08046040 (SEA-CD70), a Nonfucosylated CD70-Directed Antibody, in Combination with Azacitidine for Patients with Myelodysplastic Syndromes (MDS): A Phase 1 Dose-Finding and Dose Expansion Study

Inclusion Matters: Effective AML Treatment with HMA/Venetoclax for Older Jehovah's Witnesses

Olutasidenib Alone or in Combination with Azacitidine in Patients with m IDH1 Myelodysplastic Syndromes/Neoplasms: Final 5-Year Data

Clinical and Molecular Characteristics of RAS and RAS-like Mutational Signature in Acute Myeloid Leukemia

An Investigator Initiated Study of RCHOP in Combination with Selinexor (KPT-330) in Diffuse Large B Cell Lymphoma and Richter Transformation

Combined Use of Ziftomenib and Selinexor Is Effective in NPM1 Mutant Acute Myeloid Leukemia

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Clonal Evolution of TP53 Configurations with Treatment Predict Prognosis in Myeloid Neoplasms

Time to Response and Overall Survival in Patients with m IDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib

U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

Longitudinal Sequencing to Investigate Clonal Evolution in Myeloid Neoplasms

Combination of Olutasidenib and Azacitidine Induces Durable Complete Remissions in m IDH1 Acute Myeloid Leukemia: A Multicohort Open-Label Phase 1/2 Trial

A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in Relapsed/Refractory AML/MDS

The Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit the Growth of MLL-r AML

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Olutasidenib Alone or in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Myelodysplastic Syndromes/Neoplasms (MDS)

Factors Impacting Response to Olutasidenib in Patients with mIDH1 Acute Myeloid Leukemia

Olutasidenib for the Treatment of mIDH1 Acute Myeloid Leukemia in Patients Relapsed or Refractory to Hematopoietic Stem Cell Transplant, Prior mIDH1 Inhibitor, or Venetoclax

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only